We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Mereo Biopharma Group Plc (MREO) ADS Each Rep 5 Shs

Sell:$3.48 Buy:$3.78 Change: $0.01 (0.27%)
Market closed |  Prices as at close on 13 December 2024 | Switch to live prices |
Sell:$3.48
Buy:$3.78
Change: $0.01 (0.27%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 13 December 2024 | Switch to live prices |
Sell:$3.48
Buy:$3.78
Change: $0.01 (0.27%)
Market closed |  Prices as at close on 13 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.

Contact details

Address:
One Cavendish Place, Fourth Floor
LONDON
W1G0QF
United Kingdom
Telephone:
+ ()
Website:
https://www.mereobiopharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MREO
ISIN:
US5894921072
Market cap:
$597.31 million
Shares in issue:
773.67 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Denise Scots-Knight
    Chief Executive Officer, Director
  • Christine Fox
    Chief Financial Officer
  • John Lewicki
    Chief Scientific Officer
  • Charles Sermon
    General Counsel and Business Development, Company Secretary
  • Alexandra Hughes-Wilson
    Chief Patient Access and Commercial Planning

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.